iTeos Therapeutics, Inc.
ITOS · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | -$0 | -$34 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $57 | $29 | $38 | $37 |
| G&A Expenses | $10 | $11 | $12 | $12 |
| SG&A Expenses | $10 | $11 | $12 | $12 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $16 | $0 | $0 | $0 |
| Operating Expenses | $84 | $40 | $49 | $49 |
| Operating Income | -$84 | -$40 | -$49 | -$49 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $7 | $7 | $13 | $6 |
| Pre-Tax Income | -$77 | -$34 | -$36 | -$43 |
| Tax Expense | $2 | $1 | $7 | $2 |
| Net Income | -$79 | -$35 | -$44 | -$45 |
| % Margin | – | – | – | – |
| EPS | -1.81 | -0.8 | -1.08 | -1.05 |
| % Growth | -126.3% | 25.9% | -2.9% | – |
| EPS Diluted | -1.81 | -0.8 | -1.08 | -1.05 |
| Weighted Avg Shares Out | 44 | 43 | 40 | 43 |
| Weighted Avg Shares Out Dil | 44 | 43 | 40 | 43 |
| Supplemental Information | – | – | – | – |
| Interest Income | $6 | $7 | $8 | $8 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$66 | -$34 | -$48 | -$48 |
| % Margin | – | – | – | – |